Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 5/20 | 0.32 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL26606841 | 0.86 | CRBN (0.55) | CRBNDDB1PKMDUT | |
| Water SCHEMBL28246784 | 0.84 | CRBN (0.52) | CRBNDDB1PKMDUTSLC28A1 | |
| SCHEMBL7650207 | 0.84 | CRBN (0.52) | CRBNDDB1PKMDUTSLC28A1 | |
| Phosphoric Acid SCHEMBL28220162 | 0.77 | CRBN (0.45) | CRBNDDB1 | |
| Pyrimidine SCHEMBL2836405 | 0.76 | CRBN (0.42) | CRBNDDB1PKMDUT | |
| Pyridine SCHEMBL27912026 | 0.76 | CRBN (0.46) | CRBNDDB1PKMDUT | |
| SCHEMBL6515465 | 0.76 | CRBN (0.44) | CRBNDDB1PKM | |
| SCHEMBL27804578 | 0.73 | CRBN (0.41) | CRBNDDB1PKMDUT | |
| Benzoyl Peroxide SCHEMBL4370687 | 0.70 | F2 (0.52) | CRBNDDB1DUT | |
| Triphosphate SCHEMBL869856 | 0.69 | ENPP1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | claimed |
| EP-4177258-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-115716850-A | Crystal form, preparation method and application of aryl phosphorus oxide compound | 成都地奥九泓制药厂 | 2023-02-28 | — | — | CN | claimed |
| CN-115677773-A | Aryl phosphorus oxygen compound and application thereof | 成都地奥九泓制药厂 | 2023-02-03 | — | — | CN | claimed |
| CN-114728994-A | Aryl phosphorus oxygen compound and application thereof | 成都地奥九泓制药厂 | 2022-07-08 | — | — | CN | claimed |
| CN-114246906-A | Application of traditional Chinese medicine composition in preparation of medicines for preventing and treating bone marrow suppression | 山东新时代药业有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-104688722-B | Purposes of the epimedium aglucone in preparation prevention or treatment bone marrow suppression drug | 鲁南制药集团股份有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-109998987-A | A kind of composite hydrogel and its preparation method and application based on natural konjaku flour | 上海理工大学 | 2019-07-12 | — | — | CN | claimed |
| CN-107174576-A | Ubenimex is in reversing tumor cellular drug resistance application | 青岛大学附属医院 | 2017-09-19 | — | — | CN | claimed |
| CN-102036653-A | Injectable sustained-release pharmaceutical formulation and the preparation method thereof | INST PHARM & TOXICOLOGY AMMS | 2011-04-27 | — | — | CN | claimed |
| US-20110091420-A1 | Injectable Sustained-Release Pharmaceutical Formulation and the Preparation Method Thereof | Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, People Liberation Ar (CN) | 2011-04-21 | — | — | US | claimed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2023143470-A1 | BIFUNCTIONAL FUSION PROTEIN, METHOD FOR PREPARING SAME, AND USE THEREOF | 赋生康(上海)生物科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4177258-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2023-05-10 | — | — | EP | disclosed |
| CN-113234064-B | Tegafur derivative and preparation method and application thereof | 西南医科大学附属中医医院 | 2022-03-29 | — | — | CN | disclosed |
| CN-105198884-B | Pentacyclic indole quinolizine that the G1/G0 phases block, its synthesis, antitumor activity and application | 首都医科大学 | 2017-08-01 | — | — | CN | disclosed |
| CN-104876937-B | Maleate, its medical composition and its use of 8 fluorine 2 { 4 [(methylamino) methyl] phenyl } 1,3,4,5 tetrahydrochysene 6H azepines * simultaneously ketone of [5,4,3 cd] indoles 6 | 辉瑞公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-103209693-A | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | LUNAN PHARM GROUP CORP | 2013-07-17 | — | — | CN | disclosed |
| CN-102036653-A | Injectable sustained-release pharmaceutical formulation and the preparation method thereof | INST PHARM & TOXICOLOGY AMMS | 2011-04-27 | — | — | CN | disclosed |
| US-20110091420-A1 | Injectable Sustained-Release Pharmaceutical Formulation and the Preparation Method Thereof | Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, People Liberation Ar (CN) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | ALK, EGFR, ROS1 | CRBN 303/4885DDB1 1739/4885PKM 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.